• Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives

    by on January 31st, 2017

    SAN RAMON, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) — Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that the Board of Directors has entered into a separation agreement with Mark W. Schwartz, Ph.D. under which Dr. Schwartz will resign from the company and its affiliates as the President, Chief Executive Officer, and member of the Board of Directors, effective today. The Board of Directors expects to appoint an Interim Chief Executive Officer in the next couple weeks. 

    The Board of Directors also announced that it is in the process of engaging an independent advisory firm to evaluate strategic alternatives for the company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this review include continuing to advance the clinical programs as a stand-alone entity, a sale of the company, a business combination, merger or reverse merger, and a license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in a transaction. While the Company evaluates its strategic alternatives, Galena’s investigator-sponsored immunotherapy trials will remain ongoing.  The Company is evaluating the appropriate time to commence the GALE-401 trial and anticipates making a definitive determination in the second half of 2017.

    “After critical assessment of the current status of the company, we believe that it is the right time to run a strategic evaluation of our opportunities as we look to maximize value for our stockholders,” said Sanford J. Hillsberg, Galena’s Chairman of the Board of Directors. “We acknowledge Mark’s six years of service with Galena and wish him well in his future endeavors.”

    About Galena Biopharma

    Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product candidates, patient enrollment in our clinical trials, as well as other statements related to the progress and timing of our development activities, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory agencies, the resolution of the pending civil and criminal government investigation and the implications for the Company’s operations and financial condition, and projected market opportunities for product candidates or that otherwise relate to future periods. As a matter of policy, Galena does not comment on or provide the market with updates as to the status of any informal expressions of interest or formal proposals or offers presented to the Company from time to time, or the course of discussions with any prospective counterparties, nor will it comment upon any rumors with regard to either of the foregoing or make a further announcement regarding the Board of Director’s consideration of any proposal or other expressions of interest until such time, if ever, that it enters into a definitive agreement for a completed transaction or is otherwise required to make an announcement. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2015 and most recent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

    NeuVax is a trademark of Galena Biopharma, Inc.

    Source: Galena Biopharma, Inc.

    CONTACT: Contact:
    Remy Bernarda 
    SVP, Investor Relations & Corporate Communications
    (925) 498-7709
  • VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target

    by on January 31st, 2017

    TEL AVIV, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (NASDAQ:VBLT), announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper, entitled, “Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration” by Mendel et al., is published online in The Journal of Immunology. VBL’s manuscript reveals that MOSPD2, a protein with a previously unknown function, regulates cell migration in human monocytes. While this first manuscript focuses on the importance of MOSPD2 in immune cells, research conducted by VBL has explored the relevance of MOSPD2 in motility and metastasis of tumor cells. These oncology-related data will be presented at the forthcoming American Association of Cancer research (AACR) conference in Washington, DC, April 1-5, 2017.

    This novel platform technology enriches VBL’s capabilities, which include the Vascular Targeting System (VTS™) gene-therapy-based platform technology lead by the Phase 3 drug candidate VB-111 (ofranergene obadenovec) and the Lecinoxoids family of small molecules which have potential applications in cardiovascular, NASH and fibrotic diseases.

    “We have been working on this project in house for several years, ever since we learned that some of our Lecinoxoid molecules inhibit monocyte migration,” said Eyal Breitbart, PhD, VP for Research at VBL. “Our experiments led to identification of MOSPD2 as a regulator of cell motility in monocytes and neutrophils, but moreover, they imply that MOSPD2 might be playing a similar role in certain tumor cells.”

    The company believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of monocyte migration in chronic inflammatory conditions, inhibition of tumor cell metastases and targeting of MOSPD2+ tumor cells. VBL’s “VB-600 series” of pipeline candidates is being developed towards these applications. The company expects to report additional findings related to MOSPD2 in Q2 2017.

    For open access to the manuscript please see: http://www.jimmunol.org/content/early/2017/01/27/jimmunol.1601662

    About VBL
    Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

    About Ofranergene Obadenovec (VB-111)
    Ofranergene obadenovec is a unique biologic agent that uses a dual mechanism to target solid tumors. Based on a non-integrating, non-replicating, Adeno 5 vector, ofranergene obadenovec utilizes VBL’s proprietary Vascular Targeting System (VTS™) to target the tumor vasculature for cancer therapy. Unlike anti-VEGF or TKIs, ofranergene obadenovec does not aim to block a specific pro-angiogenic pathway; instead, it uses an angiogenesis-specific sensor (VBL’s PPE-1-3x proprietary promoter) to specifically induce cell death in angiogenic endothelial cells in the tumor milieu. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor and shows efficacy even after failure of prior treatment with other anti-angiogenics. Moreover, ofranergene obadenovec induces specific anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells.

    Ofranergene obadenovec completed a Phase 2 study in rGBM, which showed a statistically significant improvement in overall survival in patients treated with ofranergene obadenovec through progression, compared to either patients treated with ofranergene obadenovec followed by bevacizumab alone, or to historical bevacizumab data. In a Phase 2 trial for recurrent platinum-resistant ovarian cancer, ofranergene obadenovec demonstrated a statistically significant increase in overall survival and 60% durable response rate (as measured by reduction in CA-125), approximately 2x the historical response with bevacizumab plus chemotherapy in ovarian cancer.  In a Phase 2 study in recurrent, iodine-resistant differentiated thyroid cancer, ofranergene obadenovec met the primary endpoint and provided evidence of disease stabilization and a positive safety profile. Ofranergene obadenovec has received Fast Track Designation for recurrent glioblastoma in the U.S. and orphan drug status for glioblastoma in both the U.S. and EU.

    Forward Looking Statements
    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the clinical development of ofranergene obadenovec (VB-111) and its therapeutic potential and clinical results, as well as the potential relevance of MOSPD2 in immune cells and in motility and metastasis of tumor cells. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with scientific research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2015. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

    Michael Rice
    LifeSci Advisors, LLC
    (646) 597-6979
  • Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619

    by on January 31st, 2017

    REDWOOD CITY, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed four petitions for Inter Partes Review (“IPR”) in the United States Patent and Trademark Office seeking invalidation of AbbVie’s U.S. Patent 9,085,619 (“ ‘619 patent”).  The ‘619 patent is generally directed to formulations of adalimumab that do not contain a buffer.

    “The ability of proteins to self-buffer has been known for decades.  We believe these IPRs present strong legal rationales as to why the ‘619 patent should never have issued, and these independent legal arguments provide multiple challenges to the ‘619 patent for the Patent Office to consider,” said Denny Lanfear, President and Chief Executive Officer of Coherus, noting further “these IPRs are part of our multifaceted formulation development and legal strategy for CHS-1420, our Humira biosimilar candidate, which envisions various paths for advancing an adalimumab formulation to market.  We identified formulation IP early on as a key area of focus, and legal activity including earning patents and disputing patents in this area will likely continue.  We remain committed to launching CHS-1420 once approved.”

    About Coherus BioSciences, Inc.
    Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

    Forward-Looking Statements
    Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, potential opportunities including market opportunities, expectations, goals, objectives, strategies, product pipeline, product development, and the potential benefits of its products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including Coherus’ ability to invalidate the ‘619 patent as a result of its IPR petitions, to advance its formulation and legal strategy, and to commercialize CHS-1420. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates, as well as possible patent litigation. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the Securities and Exchange Commission and its future periodic reports to be filed with the Securities and Exchange Commission.

    HUMIRA® is a registered trademark of AbbVie Biotechnology Ltd.

    CONTACT: Contact:
    Patrick O’Brien
    Senior Vice President, Investor Relations
    Coherus BioSciences, Inc.
    +1 (650) 649-3527
  • NANOBIOTIX : 2016 review and 2017 anticipated milestones

    by on January 31st, 2017

    Nanobiotix: 2016 review and 2017 anticipated milestones

    Paris, France and Cambridge, Massachusetts, USA, January 31, 2017 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones.

    1. 2016 Review

    2016: NBTXR3 clinical development

    • The Soft Tissue Sarcoma (STS) PII/III trial has progressed well (one trial through Europe and Asia)

    This indication is the most advanced in Nanobiotix’s pipeline. The “Act.In.Sarc” pivotal trial (www.actinsarc.com), is currently ongoing in 13 countries through Europe and Asia (via PharmaEngine).

    In November, Nanobiotix announced that the target of 104 patients (2/3 of patients) needed for the interim readout was reached, with 115 patients randomized and 153 having signed the inform consent out of the total of 156 STS evaluable patients expected in this trial.

    • Head and Neck cancer positive interim results in European PI/II trial and launch of a new PI/II trial in Asia

    The Company reported preliminary positive results from phase I/II trial (treated with radiotherapy alone plus NBTXR3) in July. Safety and feasibility have been achieved at the first 3 dose levels and data has shown preliminary positive signs of antitumoral effect in all evaluable patients.

    PharmaEngine, Nanobiotix’s partner for the Asia-Pacific area, has launched a new clinical trial in October in head and neck cancer patients treated with radiotherapy and NBTXR3 plus chemotherapy.  This is the seventh clinical trial with NBTXR3.

    • Prostate cancer trial launch in the U.S.

    Nanobiotix announced that the US Food and Drug Administration (FDA) has approved the first Company’s Investigational New Drug (IND) application, allowing the Company to launch its first Phase I/II prostate cancer trial in the US.

    The recruitment of patients has started at Ronald Reagan UCLA Medical Center, Los Angeles CA. Two other centers are involved: Thomas Jefferson University Hospital PA, Philadelphia and Dana Farber Cancer Institute, Boston MA.

    • Liver cancers (HCC & met) PI/II trial in Europe, positive preliminary results

    In December Nanobiotix released positive results from phase I/II trial. Preliminary data shown feasibility and good safety of treatment with NBTXR3 in liver cancers at 10% dose level.

    2016: NBTXR3 first filing for market authorization in Europe
    According to plan, the Company filed for certification of NBTXR3 in August 2016 based on the level of clinical and scientific evidence available at that time. LNE/G-MED, the French notified body, has given guidance that the review of results for a potential CE mark could be expected in 2017.

    2016: Opening a new application in immuno-oncology for lead product NBTXR3

    Expansion into immuno-oncology, preclinical results: Proof of Concept (POC)
    After 11 months of development, the Company presented preclinical data at the annual meeting of the Society for Immunotherapy of Cancer (SITC), demonstrating that NBTXR3 actively stimulates the host immune system to attack tumor cells. Study results suggest NBTXR3’s potential to transform the tumor into an in-situ vaccine.

    On top of the Company’s core development activities, these findings could open new collaborations for NBTXR3 through combinations with other immuno-oncology drugs.

    2016: Corporate & financial events

    • U.S. reinforcement of the management

    Nanobiotix strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. These additions contribute to the strengthening of the Company’s clinical development and leverage U.S. investors’ potential, to continue the growth of the Company.

    • € 21.3M private placement

    Completion of a private placement of EUR 21.3 million. The investor base consisted primarily of life sciences specialists, the majority of which were from the United States.

    • US $1M milestone payment from Taiwan-based partner PharmaEngine

    The USD 1m payment from PharmaEngine has been triggered by the injection of the first patient undergoing treatment in Nanobiotix’ Soft Tissue Sarcoma (STS) pivotal phase in Asia.

    • € 2M Grant from Bpifrance

    In September, Bpifrance has awarded the Company an interest-free loan of €2M for Innovation (Prêt à Taux Zéro pour l’Innovation – PTZI).

    1. 2017 Forthcoming news flow: pivotal milestones

    This year the Company could receive its first market approval with NBTXR3 (CE Mark), which would open access to the product for cancer patients.

    In parallel, the ongoing clinical trials with NBTXR3 in seven indications will deliver several read-outs this year.

    The Company is also expanding its exciting developments in Immuno – Oncology (IO), broadening the potential value of NBTXR3 with new applications for the product.

    2017 should be full of remarkable events, enhancing Nanobiotix medical and scientific value and bringing Nanobiotix to the next level.

    NBTXR3 to market

    • Interim readout STS PII/III trial and commercialization plan

    Nanobiotix is expecting the analysis by an independent committee of interim STS Phase II/III results, to determine whether if the continuation of the trial is possible. Nanobiotix plans to release the conclusion of this analysis around spring 2017.

    The independent committee of experts, will (i) review the data related to the primary endpoint (Complete Pathological Response Rate), (ii) ensure the safety of all patients enrolled in the study, (iii) evaluate the quality of the data collected, and (iv) assess the continued scientific validity of the study design. This analysis will be performed on two third of the treated patients (104 patients).

    Assuming positive outcomes from the interim Phase II/III data readout, the Company will thereafter communicate its overall plan for the European commercialization of NBTXR3.

    • 1st European market authorization expected in 2017

    Nanobiotix anticipate that it may receive its first market authorization in 2017. This approval would allow Nanobiotix to start diffusing its product in European market. Following the CE marking and availability of the complete data of the Phase II/III (act.in.sarc study), the Company will commence negotiations in different countries to seek product reimbursement.

    NBTXR3 clinical expansion

    Nanobiotix continues its clinical expansion and expects to release data this year, increasing NBTXR3’s value.

    • Head and Neck cancer, PI/II data presentation and plan for next steps

    In the second half of 2017 the Company aims to present complete data from the Phase I/II trial.

    This indication holds great potential, and the Company will issue this year the clinical development plan of this indication, that could potentially take place in EU and in the U.S.

    • Prostate cancer, preliminary PI/II data

    The first trial launched in the U.S. in 2016 should deliver this year (H2 2017) preliminary PI/II data on safety and feasibility.

    • Liver metastasis and primary liver cancer: completion of Phase I recruitment, population selection for Phase II

    By the end of 2017, Nanobiotix should complete patients’ recruitment of the phase I part, and may proceed to the selection of patient population for the dose-expansion part of the trial. 

    Immuno Oncology (IO) developments

    In parallel to its core developments, Nanobiotix will continue developing its Immuno-Oncology program and present new results in 2017. 

    This program could lead at medium term to new potential collaborations with pharma companies developing immuno-oncology drugs.

    The abovementioned information are detailed in the press releases previously issued by the Company and available on its website: http://www.nanobiotix.com/_en/news/

    1. 2017 Financial calendar

    Nanobiotix will announce its financial and operating results according to the following indicative calendar:

    • February 28, 2017 – Revenue for Q4 2016
    • April 28, 2017 – 2016 Annual results
    • May 15, 2017 – Revenue for Q1
    • June 14, 2017 – Annual General Meeting Paris, France
    • July 12, 2017 – Revenue for Q2
    • August 31, 2017 – Half year results
    • November 15, 2017 – Revenue for Q3

    About NANOBIOTIX: www.nanobiotix.com

    Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

    NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

    NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

    Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.



    Sarah Gaubert
    Head of Communication and Public Affairs
    +33 (0)1 40 26 07 55
    sarah.gaubert@nanobiotix.com /




    Noël Kurdi
    Director, Investor Relations
    +1 (646) 241-4400
    noel.kurdi@nanobiotix.com / investors@nanobiotix.com

    Media relations

    France – Springbok Consultants
    Marina Rosoff
    +33 (0)6 71 58 00 34


    United States – The Ruth Group
    Kirsten Thomas
    +1 508-280-6592 Nanobiotix@theruthgroup.com



    This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the update of the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.16-0732-A01 on December 27, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

    This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.

    NBTXR3 is currently under development in clinical studies with the purpose of obtaining a CE mark in the future. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

  • Dems force delay in vote for HHS secretary

    by on January 31st, 2017

    Democrats on the Senate Finance Committee forced a delay action that would have moved the nomination of Rep. Tom Price (R-Ga.) to the Senate floor for consideration, citing ongoing concerns with stock purchases made by Rep. Price. The vote on Rep. Price’s nomination to serve as secretary of Health and Human Services was scheduled for […]

  • VIDEO: Consider PPIs as a cause of cutaneous reactions

    by on January 31st, 2017

    AT SDEF HAWAII DERMATOLOGY SEMINAR WAILEA, HAWAII (FRONTLINE MEDICAL NEWS) – Any proton pump inhibitor (PPI) has the potential to cause skin reactions, so it is important to ask patients about their use, according to J. Mark Jackson, MD, of the University of Louisville (Ky.). If patients are going to react to a PPI, they […]

  • VIDEO: Experts offer patch testing tips for AD patients

    by on January 31st, 2017

    AT SDEF HAWAII DERMATOLOGY SEMINAR WAILEA, HAWAII (FRONTLINE MEDICAL NEWS) – Many atopic dermatitis patients with refractory disease may have also developed allergic contact dermatitis, according to Jonathan Silverberg, MD, of Northwestern University in Chicago. Clinically, there is often overlap between AD and allergic contact dermatitis, said Dr. Silverberg , who was involved in the […]

  • Recreational marijuana use should not rule out ADHD stimulant treatment

    by on January 31st, 2017

    EXPERT ANALYSIS AT THE PSYCHOPHARMACOLOGY UPDATE INSTITUTE SAN FRANCISCO – “If one is going to say ‘you need 6 months of abstinence from cannabis before I am going to treat your ADHD,’ that’s absurd. If [kids] are stoned all the time, no, but if it’s intermittent, it’s really not a factor,” according to James J. […]

  • Clinical Guidelines: ADA 2017 Standards of Medical Care in Diabetes

    by on January 31st, 2017

    In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Of this number, 21 million were diagnosed, and 8.1 million were undiagnosed. Each year almost 1.5 million Americans receive a new diagnosis of diabetes. The management of diabetes relies upon excellent primary care. Each year the American Diabetes Association reviews new evidence and […]

  • As-needed anticoagulation for intermittent Afib raises concerns

    by on January 31st, 2017

    AT AF SYMPOSIUM 2017 ORLANDO (FRONTLINE MEDICAL NEWS) – A pilot study that suggested as-needed anticoagulation could be effective in preventing stroke in at least some patients after successful ablation of atrial fibrillation (AF) was received with caution at the annual International AF Symposium. The positive findings, originally reported at the 2016 annual meeting of […]

  • Don’t miss these drug reactions

    by on January 31st, 2017

    AT SDEF HAWAII DERMATOLOGY SEMINAR WAILEA, HAWAII (FRONTLINE MEDICAL NEWS) – New drugs can mean new drug reactions affecting the skin, notably those associated with hepatitis C therapies and new cancer drugs, according to J. Mark Jackson, MD, of the University of Louisville (Ky.). When dermatologists recognize the side effects from hepatitis C and cancer […]

  • Stroke rates high when catheter ablation of AF fails

    by on January 31st, 2017

    AT THE AF SYMPOSIUM 2017 ORLANDO (FRONTLINE MEDICAL NEWS) – In patients with atrial fibrillation (AF) who fail to achieve rhythm control after catheter ablation, the risk of ischemic stroke may approach 30% over 5 or more years of follow-up, despite optimized anticoagulation therapy, according to data from 1,002 consecutive patients presented at the annual […]

  • Strokes cut by extended NOAC prophylaxis in hospitalized, medically ill patients

    by on January 31st, 2017

    AT THE AHA SCIENTIFIC SESSIONS NEW ORLEANS (FRONTLINE MEDICAL NEWS) – Thromboprophylaxis for 35-42 days with the new oral anticoagulant betrixaban led to a significant reduction in all-cause and ischemic strokes in medically ill patients who required hospitalization as compared with conventional prophylaxis for 10 days, based on a post-hoc analysis of data from a […]

Back to top